VOLITIONRX LTD
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
VNRX$0.18-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(Expressed in United States Dollars)
| For the Years Ended | ||
|---|---|---|
| December 31, 2024 | December 31, 2023 | |
| $ | $ | |
| Operating Activities: | ||
| Net loss | (27,257,985) | (35,677,074) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,113,184 | 1,152,534 |
| Amortization of operating lease right-of-use assets | 225,748 | 260,743 |
| Loss on disposal of fixed assets | 34,731 | 15,843 |
| Stock based compensation | 1,268,543 | 2,289,545 |
| Gain on change in fair value of warrant liability | (28,763) | (240,311) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 132,045 | (169,666) |
| Prepaid expenses | 182,710 | 263,550 |
| Other current assets | 16,980 | 87,441 |
| Accounts payable and accrued liabilities | (1,217,013) | 1,224,743 |
| Deferred revenue | (106,600) | 13,000,000 |
| Management and directors’ fees payable | - | (11,494) |
| Operating lease liabilities | (257,204) | (258,853) |
| Net Cash Used In Operating Activities | (25,893,624) | (18,062,999) |
| Investing Activities: | ||
| Purchases of property and equipment | (277,499) | (1,083,749) |
| Purchase of license | (296,353) | - |
| Net Cash Used In Investing Activities | (573,852) | (1,083,749) |
| Financing Activities: | ||
| Net proceeds from issuance of common shares | 8,592,177 | 28,388,036 |
| Tax withholdings paid related to stock-based compensation | (139,939) | (203,878) |
| Common stock repurchased | - | (31,772) |
| Proceeds from grants repayable | - | 25,315 |
| Proceeds from long-term debt | 1,368,502 | 1,854,877 |
| Payments on long-term debt | (1,087,550) | (981,291) |
| Payments on grants repayable | (28,213) | (22,096) |
| Payments on financing leases | (47,723) | (46,506) |
| Net Cash Provided By Financing Activities | 8,657,254 | 28,982,685 |
| Effect of foreign exchange on cash and cash equivalents | 344,668 | 26,996 |
| Net Change in Cash and Cash Equivalents | (17,465,554) | 9,862,933 |
| Cash and Cash Equivalents – Beginning of Year | 20,729,983 | 10,867,050 |
| Cash and Cash Equivalents – End of Year | 3,264,429 | 20,729,983 |
| Supplemental Disclosures of Cash Flow Information: | ||
| Cash paid for Interest | 340,362 | 221,622 |
| Non-Cash Investing and Financing Activities: | ||
| Common stock issued for settlement of vested RSUs | 731 | 658 |
| Common stock issued for license rights | 125,258 | - |
| Offering costs from issuance of common stock | 325,090 | 392,822 |
| Fair value of warrants issued in connection with public offering at issuance | - | 366,960 |
| Non-cash note payable | 294,603 | 356,258 |
| (The accompanying notes are an integral part of these consolidated financial statements) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.